HIV infection and cardiovascular disease

European Heart Journal

Volumn 35, Issue 21, 2014, Pages 1373-1381

  Hemkens, Lars G ^a   Bucher, Heiner C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Adverse events; Antiretroviral therapy; Cardiovascular disease; Coronary heart disease; HIV infection

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CALCIUM CHANNEL BLOCKING AGENT; CANAKINUMAB; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; FOSAMPRENAVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; INSULIN; INTERLEUKIN 6; LOPINAVIR PLUS RITONAVIR; METHOTREXATE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; TRIACYLGLYCEROL; UNINDEXED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ATHEROSCLEROSIS; BLOOD PRESSURE; BODY FAT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; DEATH; DIABETES MELLITUS; DYSLIPIDEMIA; ETHNICITY; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPODYSTROPHY; META ANALYSIS (TOPIC); MORTALITY; PATIENT COUNSELING; PR INTERVAL; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; COMPLICATION; DIABETIC ANGIOPATHY; DRUG INTERACTION; HIV ASSOCIATED LIPODYSTROPHY; PHYSIOLOGY; PROCEDURES; VASCULITIS; VIROLOGY;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; DRUG INTERACTIONS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; VASCULITIS;

EID: 84902001402     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht528     Document Type: Review

References (85)

1. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chene G. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: Evidence from a large European observational cohort collaboration. Int J Epidemiol 2012;41:433-445
2. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: A systematic review and meta-Analysis. HIV Med 2012;13: 453-468
3. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97: 1837-1847. (Pubitemid 28213628
4. Althoff KN, Gange SJ. Acritical epidemiological reviewof cardiovascular disease risk in HIV-infected adults: The importance of the HIV-uninfected comparison group, confounding, and competing risks. HIV Med 2013;14:191-192
5. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506-2512. (Pubitemid 47037350
6. Klein D, Hurley LB, QuesenberryCP Jr, Sidney S.Doprotease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?. J Acquir Immune Defic Syndr 2002;30:471-477
7. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: A cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Defic Syndr 2011;57:245-253
8. Data Collection on Adverse Events of Anti H. I. V. drugs Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte A, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS 2010;24:1537-1548
9. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, D. A. D. study group. Cardiovascular disease risk factors in HIV patients-Association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-1193
10. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC, Swiss H. I. V. Cohort Study. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: The Swiss HIV Cohort Study. HIV Med 2006;7: 404-410. (Pubitemid 44123252
11. Nuesch R, Wang Q, Elzi L, Bernasconi E, Weber R, Cavassini M, Vernazza P, Thurnheer MC, Calmy A, Battegay M, Bucher HC, the Swiss HIVCS. Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). J Acquir Immune Defic Syndr 2013;62:396-404
12. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-2982. (Pubitemid 37430100
13. Grunfeld C, Pang M, DoerrlerW, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74: 1045-1052
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf Accessed 27 May 2013
15. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Wirtz V, Lataillade M, Absalon J, McGrath D, Castle Study Team. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53: 323-332
16. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, JahedNC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC, Aids Clinical Trials Group Study A Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011;154:445-456
17. Worm SW, Kamara DA, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D'Arminio Monforte A, De Wit S, Petoumenos K, Friis-Mller N, Mercie P, Lundgren JD, Sabin C. Elevated triglycerides and risk of myocardial infarction in HIVpositive persons. AIDS 2011;25:1497-1504
18. Riddler SA, Li X, Otvos J, Post W, Palella F, Kingsley L, Visscher B, Jacobson LP, Sharrett AR, Multicenter Aids Cohort Study. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008;48:281-288
19. Bucher HC, Richter W, Glass TR, Magenta L, Wang Q, Cavassini M, Vernazza P, Hirschel B,Weber R, Furrer H, Battegay M, Bernasconi E. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2012;60: 135-142
20. Stanley TL, Grinspoon SK. Body composition and metabolic changes in HIV-infected patients. J Infect Dis 2012;205(Suppl 3):S383-S390
21. Grunfeld C, Saag M, Cofrancesco J Jr, Lewis CE, Kronmal R, Heymsfield S, Tien PC, Bacchetti P, Shlipak M, Scherzer R, Study of Fat Redistribution Metabolic Change in H. I. V. Infection. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-Associated lipoatrophy. AIDS 2010;24:1717-1726
22. Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC. Lipid profiles for antiretroviral-naive patients starting PI-And NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005;10:585-591. (Pubitemid 41224950
23. De Luca A, Nasi M, Di Giambenedetto S, Cozzi-Lepri A, Pinti M, Marzocchetti A, Mussini C, Fabbiani M, Bracciale L, Cauda R, Cossarizza A. MitochondrialDNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-Term antiretroviral therapy. J Acquir Immune Defic Syndr 2012;59:113-120
24. Scherzer R, ShenW, Bacchetti P, Kotler D, Lewis CE, Shlipak MG, Heymsfield SB, Grunfeld C, Study of Fat Redistribution Metabolic Change in H. I. V. Infection. Simple anthropometric measures correlate with metabolic risk indicators as strongly as magnetic resonance imaging-measured adipose tissue depots in both HIV-infected and control subjects. Am J Clin Nutr 2008;87:1809-1817
25. Grunfeld C, Rimland D, Gibert CL, PowderlyWG,Sidney S, Shlipak MG, Bacchetti P, Scherzer R, Haffner S, Heymsfield SB. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr 2007;46:283-290. (Pubitemid 350287354
26. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, Grunfeld C, Fram Study Investigators. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008;48:44-52. (Pubitemid 351600858
27. Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB. Lipodystrophy: Metabolic insights from a rare disorder. J Endocrinol 2010;207:245-255
28. Johnson JA, Albu JB, Engelson ES, Fried SK, Inada Y, Ionescu G, Kotler DP. Increased systemic and adipose tissue cytokines in patients with HIV-Associated lipodystrophy. Am J Physiol Endocrinol Metab 2004;286:E261-E271. (Pubitemid 38140318
29. Lake JE,Wohl D, Scherzer R, Grunfeld C, Tien PC, Sidney S, Currier JS. Regional fat deposition and cardiovascular risk in HIV infection: The FRAM study. AIDS Care 2011; 23:929-938
30. Guaraldi G, Stentarelli C, Zona S, Orlando G, Carli F, Ligabue G, Lattanzi A, Zaccherini G, Rossi R, Modena MG, Alexopoulos N, Palella F, Raggi P. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010;208:222-227
31. Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, Shlipak MG, Grunfeld C, Study of Fat Redistribution Metabolic Change in H. I. V. Infection. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 2011;25:1405-1414
32. Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: A randomized controlled trial. JAMA 2008;300:509-519
33. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000;284:472-477. (Pubitemid 30484481
34. Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Moller N, Lundgren JD, Law MG, D. A. D. Study Group. Predicting the short-Term risk of diabetes in HIV-positive patients: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc 2012;15:17426
35. Rasmussen LD, Mathiesen ER, Kronborg G, Pedersen C, Gerstoft J, Obel N. Risk of diabetes mellitus in persons with and without HIV: A Danish nationwide populationbased cohort study. PLoS One 2012;7:e44575
36. Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, Protopopescu C, Leport C, Raffi F, Chene G, Anrs Co Aproco-Copilote Cohort Study Group. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012;26:303-314
37. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte A, Fontas E, Law MG, Friis-Moller N, Phillips A, Data Collection on Adverse Events of Anti H. I. V. Drugs study. Incidence and risk factors for new-onset diabetes in HIV-infected patients: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008;31:1224-1229
38. MurataH, HruzPW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-4. (Pubitemid 30457596
39. Koster JC, Remedi MS, Qiu H, NicholsCG,HruzPW.HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003;52:1695-1700. (Pubitemid 36792459
40. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010;33:2244-2249
41. Strategies for Management of Antiretroviral Therapy Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296
42. Kuller LH, Tracy R, BellosoW, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD, Insight Smart Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203
43. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon D, Paton NI, Prineas RJ, Neaton JD, Insight Smart Study Group. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012;7:e44454
44. Neuhaus J, JacobsDR Jr, Baker JV,Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795
45. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, Goetz M, Tracy R, Oursler KK, Rimland D, Crothers K, Rodriguez-Barradas M, Crystal S, Gordon A, Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks SG, Rinaldo C, Kuller LH, Justice A, Freiberg M. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012;55: 126-136
46. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Sax PE. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012;26:1371-1385
47. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Epling L, Van Natta M, Medvik K, Huang Y, Deeks SG, Martin JN, Meinert C, Lederman MM. Gut epithelial barrier dysfunction, inflammation, and coagulation predict higher mortality during treated HIV/AIDS. CROI 2012
48. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, Ubolyam S, Carr A, Ruxungtham K, Hirschel B, Ananworanich J, Staccato Study Group. HIV increases markers of cardiovascular risk: Results from a randomized, treatment interruption trial. AIDS 2009;23:929-939
49. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M, Swiss HIVCS. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002;185:456-462. (Pubitemid 34142807
50. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC, Insight Smart Study Group. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203:780-790
51. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, Corsini E, Abdelbaky A, Zanni MV, Hoffmann U, Williams KC, Lo J, Grinspoon SK. Arterial inflammation in patients with HIV. JAMA 2012;308:379-386
52. Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, Neuhaus J, Paton NI, Friis-Moller N, Lampe F, Liappis AP, Neaton JD, Group ISS. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009;207:524-529
53. Aristoteli LP, Moller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006;184:342-347. (Pubitemid 43049718
54. Lo J, Plutzky J. The biology of atherosclerosis: General paradigms and distinct pathogenic mechanisms among HIV-infected patients. J Infect Dis 2012;205(Suppl 3): S368-S374
55. Hsue PY, Ordovas K, LeeT, Reddy G, GotwayM, Schnell A,HoJE, SelbyV, Madden E, Martin JN, Deeks SG, Ganz P,Waters DD. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol 2012;109:742-747
56. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, Wein N, Holodniy M, Hou N, Owens DK, Desai M. Risk of cardiovascular disease from antiretroviral therapy for HIV: A systematic review. PLoS One 2013;8:e59551
57. D. A. D. Study Group, Sabin CA,Worm SW,Weber R, Reiss P, El-SadrW, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Moller N, Kirk O, Pradier C,Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multicohort collaboration. Lancet 2008;371:1417-1426
58. Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, Mengoli C, Parisi SG, Moyle G. Abacavir use and cardiovascular disease events: A meta-Analysis of published and unpublished data. AIDS 2011;25:1993-2004
59. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, Marcus KA. No association of abacavir use with myocardial infarction: Findings of an FDA meta-Analysis. J Acquir Immune Defic Syndr 2012;61:441-447
60. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Moller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318-330
61. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, Capeau J, Cohen A. HIV and coronary heart disease: Time for a better understanding. J Am Coll Cardiol 2013;61:511-523
62. Friis-Moller N, Thiebaut R, Reiss P,Weber R, Monforte AD, De Wit S, El-SadrW, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG, D. A. D. study group. Predicting the risk of cardiovascular disease in HIV-infected patients: The data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010;17:491-501
63. D'AgostinoRBSr. Cardiovascular risk estimation in 2012: Lessons learned and applicability to the HIV population. J Infect Dis 2012;205(Suppl 3):S362-S367
64. Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Moller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M, D. A. D. Study Group. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: Results from the D:A:D study. HIV Med 2011; 12:412-421
65. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001;15:1503-1508. (Pubitemid 32744597
66. Bonnet F, Aurillac-Lavignolle V, Breilh D, Thiebaut R, Peuchant E, Bernard N, Lacoste D, Dabis F, Beylot J, Chene G, Morlat P, GESCA. Pravastatin in HIV-infected patients treated with protease inhibitors: A placebo-controlled randomized study. HIV Clin Trials 2007;8:53-60
67. Calza L, Manfredi R, Colangeli V, Tampellini L, Sebastiani T, Pocaterra D, Chiodo F. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005;19:1051-1058. (Pubitemid 40961145
68. Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, Acosta EP, Connick E, Wohl D, Kojic EM, Benson CA, Aberg JA. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: Results of ACTG A5186. J Acquir Immune Defic Syndr 2008;47:459-466. (Pubitemid 351366958
69. Balasubramanyam A, Coraza I, Smith EO, Scott LW, Patel P, Iyer D, Taylor AA, Giordano TP, Sekhar RV, Clark P, Cuevas-Sanchez E, Kamble S, Ballantyne CM, Pownall HJ. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: Results of 'heart positive,' a randomized, controlled trial. J Clin Endocrinol Metab 2011;96:2236-2247
70. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: A systematic review and meta-Analysis. Lancet 2010;375:1875-1884
71. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: A systematic review. Arch Intern Med 2005; 165:725-730. (Pubitemid 40569423
72. Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267
73. Origin Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, RamachandranA, Riddle MC, Ryden LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012; 367:309-318
74. Risk Prevention Study Collaborative Group, RoncaglioniMC, Tombesi M,Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368:1800-1808
75. Smith MEB, Lee NJ, Haney E, Carson S. Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5 [Internet]. Portland (OR): Oregon Health & Science University; 2009 Nov. Available from:. http://www.ncbi.nlm.nih.gov/ books/NBK47273/. Accessed 27 May 2013
76. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD, D. A. D. Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D study. J Infect Dis 2013; 207:1359-1369
77. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-infected individuals: Traditional and HIV-related factors. Am J Kidney Dis 2012; 59:628-635
78. (EACS) EACS. EACS Guidelines Version 6.1, November 2012. http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelinesv6. 1-2edition.pdf. Accessed 30 May 2013
79. Balt CA. Hypertension and HIV infection. J Assoc Nurses AIDS Care 2013;24(Suppl): S127-S134
80. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, KoenigW, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Jupiter Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
81. ClinicalTrials.gov. Effect of rosuvastatin on endothelial function. http:// clinicaltrials.gov/show/NCT00986999. Accessed 30 May 2013
82. ClinicalTrials.gov. Use of rosuvastatin in HIV-infected subjects to modulate cardiovascular risks. http://clinicaltrials.gov/show/NCT01218802. Accessed 30 May 2013
83. ClinicalTrials.gov. Aspirin and Antiretroviral Therapy in HIV Infected Patients. http://clinicaltrials.gov/show/NCT00783614. Accessed 30 May 2013
84. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: Scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009;7(Suppl 1):332-339
85. Ridker PM, Howard CP,Walter V, Everett B, Libby P, Hensen J, Thuren T, Cantos Pilot Investigative Group. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: A phase IIb randomized, placebo-controlled trial. Circulation 2012;126:2739-2748.